1. "Lymphoma"
Formats
  1. Meeting Abstract (1340)
  2. Journal Article (1048)
  3. Book Section (63)
  4. Review (63)
  5. Editorial (37)
  6. Research Letter (35)
  7. Guidelines (18)
  8. Conference Paper (15)
  9. Correspondence (11)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2639)
  2. Department of Medicine (2639)
  3. Hematologic Malignancies, Division of (2639)
  4. Lymphoma (2639)
  5. Population Sciences Research Program (720)
  6. Survivorship Research (633)

More Groups

People
  1. Andrew Zelenetz (767)
  2. Steven Horwitz (645)
  3. Maria Palomba (415)
  4. David Straus (356)
  5. Ariela Noy (351)
  6. Alison Moskowitz (339)

More People

Years
  1. 2025 (28)
  2. 2024 (100)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (833)
  2. Journal of Clinical Oncology (274)
  3. Hematological Oncology (110)
  4. Leukemia and Lymphoma (81)
  5. British Journal of Haematology (79)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (898)
  2. American Society of Clinical Oncology (290)
  3. Elsevier Inc. (187)
  4. Wiley Blackwell (173)
  5. John Wiley & Sons (95)
  6. Nature Publishing Group (92)

More Publishers

Results (2639)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Surveillance imaging for lymphoma: Pros and cons
    Journal Article

    Lynch, R. C.; Zelenetz, A. D.; Armitage, J. O.; Carson, K. R.
    American Society of Clinical Oncology Educational Book (2014)

    Fulltext@MSK | Save
  • Personalizing therapy for older adults with lymphoid malignancies: Options and obstacles
    Journal Article

    Wildes, T. M.; Goede, V.; Hamlin, P.
    American Society of Clinical Oncology Educational Book (2014)

    Fulltext@MSK | Save
  • Diffuse large B-cell lymphoma
    Book Section

    Zelenetz, A. D.
    In Abutalib, S. A.; Markman, M. (Eds.) Cancer Consult: Expertise for Clinical Practice (2014)

    Fulltext@MSK | Save
  • Evolution of CD30 as a target in Hodgkin lymphoma, mature t-cell lymphoma, and other lymphomas
    Journal Article

    Younes, A.
    Clinical Advances in Hematology & Oncology (2014)

    Fulltext@MSK | Save
  • A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) us subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Younes, A.; Zinzani, P. L.; Sehn, L. H.; Johnson, P. W. M.; Gascoyne, R. D.; Ahmedi, T.; Bellew, K. M.; Vermeulen, J.; Zhuang, S. H.; Sun, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Preliminary findings from a phase I, multicenter, open-label study of the anti-CD37 antibody-drug conjugate (ADC), IMGN529, in adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL)
    Meeting Abstract

    Stathis, A.; Maddocks, K. J.; Flinn, I.; Mejia, A.; Palomba, M. L.; Zildjian, S.; Murphy, M.; Deckert, J.; Ruiz-Soto, R.; Freedman, A.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial
    Meeting Abstract

    Sharman, J. P.; Coutre, S. E.; Furman, R. R.; Cheson, B. D.; Pagel, J. M.; Hillmen, P.; Barrientos, J. C.; Zelenetz, A. D.; Kipps, T. J.; Flinn, I.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Clinical and histologic characterization of dermatologic adverse events front the pan-PI3K inhibitor buparlisib (BKM-120)
    Meeting Abstract

    Schindler, K.; Abraham, R.; Shah, P. D.; Chandarlapaty, S.; Paik, P. K.; Bell-Mcguinn, K.; Bajorin, D. F.; Mellinghoff, I. K.; Younes, A.; Gounder, M. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Circulating tumor cells (CTCs) and LDH as prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing during or following docetaxel treated in the orteronel phase 3 ELM-PC 5 trial
    Meeting Abstract

    Scher, H. I.; Fizazi, K.; Lee, C.; Maclean, D.; Tejura, B.; Webb, I. J.; Borgstein, N.; Dreicer, R.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab) or investigator's choice of chemotherapy in subjects with relapsed or refractory adult T-cell leukemia-lymphoma (ATL)
    Meeting Abstract

    Phillips, A. A.; Fields, P.; Hermine, O.; Taylor, G.; DelloukIna, M. L.; Horwitz, S. M.; Ramos, J. C.; Menlane, J. C.; Barta, S. K.; Or, K. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save